Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effectiveness, safety, and tolerability of a
study drug called fedratinib in participants with myelodysplastic/myeloproliferative
neoplasms (MDS/MPNs) and chronic neutrophilic leukemia (CNL).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute